WELLS FARGO & COMPANY/MN
Position in INTS — Intensity Therapeutics, Inc.
CIK 72971
SAN FRANCISCO, CA
Position in INTS
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$1,176
-$12,003 QoQ
Shares Held
200
+44.9% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WELLS FARGO & COMPANY/MN holds $1,567,775,023 across 417 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
749,528 | $372,313,040 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
1,390,428 | $108,828,797 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
310,047 | $93,333,446 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
140,802 | $87,795,677 | |
| 5 | EXEL |
Exelixis, Inc.
|
717,840 | $39,057,673 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
178,780 | $33,481,916 | |
| 7 | ARGX |
Argenx SE
|
34,453 | $31,964,458 | |
| 8 | INCY |
Incyte Corp
|
255,064 | $28,914,053 |
All Filings in INTS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,176 | 200 | Shares | Defined | 2026-05-11 | |
| 2024-09-30 | $13,179 | 3,450 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $16,905 | 3,450 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $12,906 | 2,482 | Shares | Defined | 2024-05-10 | |
| 2023-12-31 | $21,261 | 2,481 | Shares | Defined | 2024-02-09 | |
| 2023-09-30 | $9,845 | 2,480 | Shares | Defined | 2023-11-13 | |
| No filing history on record for this holder in this stock. | ||||||